Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2009. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in Ordinary share American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific insider transaction notification and does not contain financial performance data.
Material Changes
The only material change disclosed is a reduction in shareholding by a connected person:
- Person: Mr. W C Louv
- Transaction Date: August 10, 2009
- Transaction Type: Sale of Ordinary share ADRs
- Volume: 1,964 ADRs
- Price: $39.02 per ADR
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to the requirements of Disclosure and Transparency Rule 3.1.4R(1)(a) regarding the notification of the aforementioned transaction.
Investor Verification Checklist
- Verify the total number of ADRs held by Mr. W C Louv following the sale of 1,964 shares.
- Confirm the market price of GSK ADRs on August 10, 2009, to validate the reported transaction price of $39.02.
- Review subsequent filings to determine if this transaction was part of a larger divestment plan by the individual.